Thanks to the generous support of our patients, families, caregivers, corporate supporters, and the many friends of the Mesothelioma Applied Research Foundation, we are pleased to announce that the 2021 grant cycle for mesothelioma research funding is now accepting pre-application letters of intent (LOI) until 11:59 PM ET Monday, Nov. 15, 2021 on proposalCENTRAL. Our research grant program offers $100,000 grants for two years ($50,000 per year). Please read the below before applying. Read more about the Meso Foundation’s Research Grant Program.
Who Can Apply:
- Investigators who have a doctoral-level degree and a full-time faculty position or equivalent at a college, university, medical school, or eligible not-for-profit research organization globally.
- Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.
Additional information to be included in the LOI to obtain mesothelioma research funding:
- All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2021 Areas of Interest (listed below).
- All projects must be feasible within the timeline and budgetary constraints of the current RFA.
- All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.
Areas of Interest 2021 (not listed in order of priority):
- Novel therapies for mesothelioma for both pleural and peritoneal (focus on – targeted therapies, combination immunotherapy, cellular therapy, virotherapy)
- Novel strategies for screening and early detection
- Novel strategies for risk assessment and prognosis stratification
- Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection and management)
- Improving personalization of therapies (gender and racial differences, targeted therapies and predictive biomarkers)
- Mechanisms of treatment resistance/failure
- Improvement of quality of life in mesothelioma patients including treatment-related fibrosis, treatment-related toxicities, other adverse events, and survivorship issues
- Improvement of mental health in mesothelioma patients and caregivers
- Mesothelioma biology and etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment)
For questions, please contact Meghan Butler, Development Coordinator, at [email protected] or 703-879-3824.
